Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Albumin-bound docetaxel - CSPC ZhongQi Pharmaceutical Technology

Next Previous
Drug Profile

Albumin-bound docetaxel - CSPC ZhongQi Pharmaceutical Technology

Alternative Names: CPO-100; Docetaxel albumin-bound; Docetaxel for injection (albumin-bound); Docetaxel nanoparticle formulated with human albumin - CSPC ZhongQi Pharmaceutical Technology; DTX-HSA; HB-1801

Latest Information Update: 09 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSPC ZhongQi Pharmaceutical Technology
  • Developer Conjupro Biotherapeutics; CSPC ZhongQi Pharmaceutical Technology
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Gastric cancer; HER2 positive breast cancer
  • Phase II Adenocarcinoma; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours
  • Phase I/II Squamous cell cancer

Most Recent Events

  • 04 Sep 2026 CSPC ZhongQi Pharmaceutical Technology plans a phase III trial for HER2-negative breast cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in China (IV, Infusion) in August 2026 (NCT07805135) (CTR20263268)
  • 28 Jul 2026 No recent reports of development identified for phase-I development in Solid-tumours(In the elderly, Late-stage disease, Metastatic disease, In adults) in China (IV, Infusion)
  • 28 Jul 2026 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top